Skip to main content
ENDO 2026 Main banner

Joseph G. Verbalis, MD

Chief, Div of Endo and Metab
Georgetown University
Washington, DC, United States

Joseph G. Verbalis, MD, graduated from Princeton University with an AB in chemistry in 1971, and received an MD from the University of Pittsburgh in 1975. He completed his residency training at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania from 1975-1978 and his fellowship training in endocrinology and metabolism at the University of Pittsburgh from 1978-1980. Dr. Verbalis was a faculty member at the University of Pittsburgh from 1980 through 1995 where he rose to the position of tenured Professor of Medicine, and then relocated to Georgetown University in Washington, DC where he served as the Chief of the Division of Endocrinology and Metabolism from 1995-2004, and then as the Interim Chair of the Department of Medicine from 2004-2007. Dr. Verbalis is currently a Professor of Medicine and Physiology, Chief of the Division of Endocrinology and Metabolism, and Co-Director of the Georgetown-Howard Universities Center for Clinical and Translational Science.

Dr. Verbalis has published more than 250 journal articles and book chapters related to the neuroendocrine regulation of the hormones vasopressin and oxytocin, and disorders of body fluid homeostasis. He authors the chapters on vasopressin and water metabolism in major textbooks of endocrinology (Williams Textbook of Endocrinology, nephrology (Brenner & Rector's The Kidney; Diseases of the Kidney and Urinary Tract), and neuroscience (Fundamental Neuroscience). He is a regularly an invited speaker at national and international meetings on neuroendocrinology and body fluid homeostasis.

Dr. Verbalis' research has been continuously funded by the NIH for the last 20 years and recently has concentrated on mechanisms underlying adaptation to hyponatremia, renal escape from vasopressin, osmotic regulation of hypothalamic gene expression, sex differences in physiology and pathophysiology, exercise-associated hyponatremia and clinical use of vasopressin receptor antagonists.

Disclosure information not submitted.

Presentation(s):